MENVEO
STN: 125300
Proper Name: Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
Tradename: MENVEO
Manufacturer: GlaxoSmithKline Biologicals SA
Indication:
- MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55 years of age.
Product Information
Supporting Documents
- August 30, 2024 Approval Letter - MENVEO
- October 14, 2022 Approval Letter - MENVEO
- July 28, 2020 Approval Letter - MENVEO
- February 20, 2020 Approval Letter - MENVEO
- December 20, 2019 Approval Letter - MENVEO
- September 26, 2019 Approval Letter - MENVEO
- October 4, 2018 Approval Letter - MENVEO
- Approval History, Letters, Reviews, and Related Documents - Menveo
- Supporting Documents older than three years - MENVEO